Key Takeaways
- Resilient quarter in a weak market: Consolidated revenue grew 6% to ₹865 Cr, with gross margins expanding 350 bps to 70.1% and EBITDA up 20%, even as rural demand stayed muted and mass-consumer brands declined.
- The margin story is the strongest card: Management is confident of ending the year with at least 200 bps margin expansion, citing benign raw material costs and judicious price hikes as durable tailwinds.
- Portfolio divergence is widening: Premium, urban-led bets (Navratna, Dermi Cool, Helios/Brillare) are growing double digits, while mass-market staples (Boroplus, Kesh King, male grooming) are shrinking, exposing a split that a rural recovery alone may not fully heal.
- Winter and rural recovery are the swing factors: With no stock loading done yet and Diwali falling mid-November, the entire winter portfolio’s fate and the full-year top-line trajectory hinge on post-festive secondary demand and a rural pickup that management cannot time.
- What to watch next quarter: Whether winter product offtake materializes post-Diwali, whether Kesh King returns to growth as promotions resume, and whether the CIS business bounces back from its one-off weak quarter.
Demand & Channel Dynamics
- Rural still waiting: Demand in rural markets remains muted, and management is explicit that it cannot call the timing of a recovery. Project Khoj, now covering ~60,000 villages, is positioned as a defensive moat that prevented decline rather than a growth engine.
- Urban channels doing the lifting: Modern trade and e-commerce drove performance, and the company expects similar growth rates to continue, with further margin levers still available in both channels.
- Chemist channel quietly scaling: Reach expanded to 1,25,000 outlets with 20% growth in the channel, building a distribution asset that sits ready for when consumption returns.
- Winter loading delayed: No significant stock loading had occurred by Q2 end; loading happens in October and September, and with Diwali shifting to mid-November (vs October last year), secondary sales will only become visible post-Diwali. Markets have slightly bounced back from the July-August trough.
Mohan Goenka: "We are well prepared. We are well geared, but very difficult to say when the market would bounce back."
Brand Portfolio Health
| Brand / Segment | Trend | Commentary |
|---|---|---|
| Navratna & Dermi Cool | ▲ 12% growth | Urban and premium demand holding up well; core growth driver in the domestic portfolio. |
| Healthcare (Zandu) | ▲ 4% growth | Q2 saw a medico-business decline after a strong Q1; the broader OTC and medico market was stagnant. Recent months have been much stronger, with high single-digit growth expected in Q3. |
| Pain Management | ▬ 1% growth | Flattish in a challenging quarter. |
| Boroplus | ▼ Single-digit decline | Hit by price-sensitive mass consumers pulling back. The franchise is diversifying beyond antiseptic cream: lotion, soap, Boroplus Soft, and Aloe Vera Gel now contribute ~20-22% of total Boroplus sales. |
| Kesh King | ▼ Single-digit decline | Decline tied to a promotional cycle: sales rise with consumer promotions and dip when they are withdrawn. Management is confident of a Q3 rebound and expects to end the year with positive growth. |
| Male Grooming (Fair and Handsome) | ▼ Single-digit decline | Brand has reached stagnancy and needs a complete re-launch, which is now in the works. |
- Winter portfolio visibility is zero: The entire category’s performance will only become clear post-Diwali, making Q3 a high-stakes quarter for a material chunk of revenue.
Premium Bets & New Forays
- Helios & Brillare Sciences: Combined revenue grew 63%, driven by premiumization, new product launches, and expansion beyond e-commerce into modern trade and large general trade stores. Together they now represent ~5% of total business, and the base is no longer negligible.
- Profitability of new ventures: Helios (TMCs) is now EBITDA breakeven; Brillare still carries a "very miniscule kind of margin erosion," per management, which declined to provide specific loss figures.
- AloFrut juice entry: The company entered the juice category via a 26% strategic equity stake in Axiom Ayurveda Private Limited, a small but notable adjacency bet outside core personal and healthcare.
- Zanducare D2C expansion: New products including copper vessels, water bottles, and glasses launched across the D2C platform, other e-commerce marketplaces, and modern trade, extending the Zandu brand into lifestyle wellness.
International Business
- Top-line momentum: International business grew 16% in constant currency and 12% in INR terms, led by the MENAP and SAARC regions, despite currency fluctuations and import restrictions in some markets.
- CIS/Russia one-off: The region had one bad quarter due to internal uncontrollable issues. Management expects a bounce-back to decent growth rates in Q3 and Q4. MPDs have decent trade-channel acceptance, though most revenue still flows through the pharmaceutical channel.
Margins & Cost Structure
- Gross margin leap: Gross margins expanded 350 bps to 70.1%, driven by lower input costs and judicious price hikes. EBITDA grew 20% to ₹234 Cr, with EBITDA margin expanding 300 bps to 27%.
- Confidence anchored in raw materials: Management stated raw material prices remain benign, making the margin outlook the more confident half of the full-year story. The company expects to exit the year with at least 200 bps of margin expansion.
- Top-line caution balances the margin optimism: While margins look secure, the revenue growth outlook is conditional on winter setting in well and rural recovery materializing, both outside the company’s control.
Mohan Goenka: "Second half margins, again Shirish I am saying that is not a concern honestly because raw material prices are still benign."
Competitive Landscape
- Muted competitive intensity: The only new competitive action noted is Dabur launching a cool oil in the category where Navratna operates. No other significant new entrants or disruptive moves were flagged.
- Distribution strategy is in harvest mode: With Project Khoj complete, no new major distribution initiatives are planned. The focus has shifted to extracting sales from the current reach and maintaining profitability, rather than further footprint expansion.
Mohan Goenka: "I am more confident on the margin front. We can recover very significantly if the winter sets in well and there is good amount of rural recovery but in this difficult times I would say 7% is also a good top line number."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Margin expansion | At least 200 bps expansion for the full year | FY24 exit |
| Top-line growth | End the year in a similar range as H1 (~7%); high single-digit achievable if winter and rural recovery cooperate | FY24 exit |
| Kesh King | Return to growth in Q3; end the year on a positive growth note | Q3 FY24 / FY24 exit |
| Healthcare (Zandu) | High single-digit growth in Q3 after a weak Q2 | Q3 FY24 |
| CIS/Russia | Bounce back to decent growth rates | Q3 and Q4 FY24 |
| Male Grooming | Complete re-launch of Fair and Handsome | No date (in development) |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Consolidated revenue | ₹865 cr, +6% YoY |
| Domestic net sales growth | +4% YoY |
| Domestic volume growth | ~2% YoY |
| Gross margin | 70.1%, expanded 350 bps YoY |
| EBITDA | ₹234 cr, +20% YoY; margin at 27%, up 300 bps |
| H1 FY24 revenue growth | ~7% YoY |
| H1 FY24 EBITDA margin | 25.1%, up 180 bps YoY |
| H1 FY24 PAT | ₹316 cr, +23% YoY |
| International business growth | +16% in constant currency, +12% in INR terms |
| Navratna and Dermi Cool range growth | +12% YoY |
| Healthcare range growth | +4% YoY |
| Pain management growth | +1% YoY |
| Boroplus, male grooming, Kesh King range | Declined in single digits YoY |
| Helios and Brillare Sciences growth | +63% YoY |
| Modern trade growth | ~17–18% YoY |
| E-commerce growth | ~50% YoY |
| E-commerce share of total business | ~13% |
| Modern trade share of total business | 11% |
| Chemist channel growth | ~20% YoY |
| Helios and Brillare combined revenue share | ~5% of total business |
| Boroplus extensions share of total Boroplus | ~20–22% |
| Interim dividend | ₹4 per share (400%) for FY2024 |
| Promoter pledge level | ~15% of promoters' holding |